Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular abnormalities in lung cancer

R Salgia1, A T Skarin

  • 1Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. ravi_salgia@dfci.harvard.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 21, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.

Oncogene·2017
Same author

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.

Oncogene·2017
Same author

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.

Oncogene·2015
Same author

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2014

Recent studies reveal key molecular abnormalities in lung cancer, including oncogene activation and tumor suppressor gene loss. Understanding these genetic changes offers potential for earlier lung cancer diagnosis and novel therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer pathogenesis involves complex molecular alterations.
  • Key oncogenes and tumor suppressor genes are frequently affected.

Purpose of the Study:

  • To review recently identified molecular abnormalities in lung cancer.
  • To discuss their diagnostic and therapeutic implications.

Main Methods:

  • Literature review using Medline database (1966-1997).
  • Inclusion of cited studies and reviews.

Main Results:

  • Common alterations include oncogene activation (RAS, MYC, c-erbB-2, BCL-2) and tumor suppressor gene loss (RB, p53, p16INK4A).
  • Specific mutations and expression changes are frequent in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).

Related Experiment Videos

  • For example, K-RAS mutations occur in up to 30% of adenocarcinomas, and RB abnormalities exceed 90% in SCLC.

    • Conclusions:

    • Genetic abnormalities are central to lung cancer development.
    • Further understanding of these molecular changes can drive earlier diagnosis and innovative treatment strategies.